Press release
Infliximab Biosimilar Insight 2024: Clinical Trials, FDA Approvals, and Companies by DelveInsight | Major players: Celltrion, Pfizer, Merck, Biocad, Celltrion
DelveInsight's "Infliximab Biosimilar Insight, 2024" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.Interested to know more about the functioning of Biosimilars, visit @ https://www.delveinsight.com/report-store/infliximab-biosimilars-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Infliximab Overview
Infliximab is a medication classified as a tumor necrosis factor (TNF) inhibitor. It is used for the treatment of various autoimmune diseases, particularly those involving chronic inflammation. Infliximab works by targeting and neutralizing tumor necrosis factor-alpha (TNF-α), a cytokine involved in the inflammatory response. By inhibiting TNF-α, Infliximab helps reduce inflammation and alleviate symptoms associated with certain autoimmune conditions.
Indications: Infliximab is commonly prescribed for conditions such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriatic arthritis, ankylosing spondylitis, and psoriasis. These are conditions where excessive TNF-α plays a role in perpetuating inflammation.
Administration: Infliximab is typically administered by intravenous infusion, usually in a healthcare setting such as a hospital or infusion center. The frequency of infusions may vary depending on the specific condition being treated.
Mechanism of Action: TNF-α is a pro-inflammatory cytokine involved in the immune response. By binding to TNF-α, Infliximab inhibits its activity, leading to a reduction in inflammation. This mechanism helps control the symptoms of autoimmune diseases and prevent further damage to tissues.
Efficacy: Infliximab has shown effectiveness in managing symptoms, improving quality of life, and slowing disease progression in various autoimmune disorders. However, it is not a cure, and its use requires careful monitoring and management by healthcare professionals.
Side Effects: Like many medications, Infliximab is associated with potential side effects. These can include an increased risk of infections, infusion reactions, and, in rare cases, serious adverse events. Patients receiving Infliximab are typically monitored closely for any signs of adverse reactions.
Precautions: Prior to starting Infliximab, healthcare providers consider the patient's medical history, including the presence of infections, and may perform screening tests. It is important for patients to inform their healthcare provider about any ongoing infections or other medical conditions before starting treatment.
Request for a detailed sample copy of our report @ https://www.delveinsight.com/sample-request/infliximab-biosimilars-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Infliximab Biosimilars: Marketed Drugs
1. Inflectra: Celltrion/Pfizer
2. Renflexis: Merck
Infliximab Biosimilars: Emerging Drugs
1. BCD 055: Biocad
2. CT-P17: Celltrion
Major Players in Infliximab
There are approximately 20+ Infliximab biosimilars key companies which are developing the therapies for Infliximab.
To understand key companies related to the Infliximab Biosimilars Market, get a snapshot @ https://www.delveinsight.com/report-store/infliximab-biosimilars-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Infliximab Biosimilars Report Highlights:
1. The companies and academics are working to assess challenges and seek opportunities that could influence Infliximab R&D. The therapies under development are focused on novel approaches to treat/improve Infliximab.
2. In July 2017, Merck had launched in the U.S. a biosimilar of Remicade (infliximab), the blockbuster immune-mediated inflammatory disorders treatment it markets outside the U.S., including Europe, while partner Janssen Biotech markets the drug stateside.
3. In December 2017, Pfizer announced that the United States (U.S.) Food and Drug Administration (FDA) has approved IXIFI (PF-06438179, infliximab-qbtx), a chimeric human-murine monoclonal antibody (mAb) against tumor necrosis factor, as a biosimilar to Remicade (infliximab) for all eligible indications of the reference product. The FDA has approved IXIFI as a treatment for patients with rheumatoid arthritis, Crohn's disease, pediatric Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.
For detailed Infliximab Biosimilars Report Highlights, visit here @ https://www.delveinsight.com/report-store/infliximab-biosimilars-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents:
1. Key Insights
2. Infliximab Biosimilars: Snapshot
3. Executive Summary
4. Regulatory Outlook For Biosimilars
5. Infliximab (Reference Product: Remicade)
6. Research and Development
7. Remicade Biosimilar: Emerging Opportunities
8. Infliximab: Biosimilars Assessment
9. Infliximab Biosimilars Profiles: By Company
10. Infliximab Biosimilars: Comparative Landscape: By Company
11. Infliximab Biosimilars: Competitive Landscape
12. Market Drivers
13. Market Barriers
14. SWOT Analysis
15. Appendix
16. Bibliography
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight
Reqest for a detailed TOC of the Infliximab Biosimilars Report @ https://www.delveinsight.com/sample-request/infliximab-biosimilars-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Trending Reports:
• Acute Pain Market: https://www.delveinsight.com/report-store/acute-pain-market
• Alopecia Aerata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market
• Neuromodulation Devices Market: https://www.delveinsight.com/report-store/neuromodulation-devices-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Parkinson's Disease Market: https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
• Brain Cancer Market: https://www.delveinsight.com/report-store/brain-cancer-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Adult Growth Hormone Deficiency Market: https://www.delveinsight.com/report-store/adult-growth-hormone-deficiency-aghd-market
• Biliary Tumor Market: https://www.delveinsight.com/report-store/biliary-tumor-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market
• Emesis Market: https://www.delveinsight.com/report-store/emesis-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/hearing-aid-devices-market
• Reactive Arthritis Market: https://www.delveinsight.com/report-store/reactive-arthritis-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Airway Stent Market Market: https://www.delveinsight.com/report-store/airway-stent-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Asphyxia Market: https://www.delveinsight.com/report-store/asphyxia-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Vitamin A Deficiency Market: https://www.delveinsight.com/report-store/vitamin-a-deficiency-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Infliximab Biosimilar Insight 2024: Clinical Trials, FDA Approvals, and Companies by DelveInsight | Major players: Celltrion, Pfizer, Merck, Biocad, Celltrion here
News-ID: 3489554 • Views: …
More Releases from DelveInsight Business Research

Vitiligo Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA App …
The "Vitiligo Pipeline Insight, 2025" report by DelveInsight delivers an in-depth view of the current clinical development scenario along with the future growth trajectory of the Vitiligo Market.
As per DelveInsight's evaluation, the global Vitiligo treatment pipeline features 20+ leading companies actively engaged in developing 20+ therapeutic candidates. The analysis covers Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and developmental updates.
The Vitiligo Pipeline report offers extensive commercial and clinical…

Myelodysplastic Syndrome Competitive Landscape 2025: Clinical Trial Analysis, Th …
DelveInsight's, "Myelodysplastic Syndrome Pipeline Insight 2025" report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Myelodysplastic Syndrome Pipeline Report
• DelveInsight's Myelodysplastic Syndrome…

Fibromyalgia Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA …
According to DelveInsight, the global Fibromyalgia pipeline features more than eight key companies actively developing over ten treatment candidates. The analysis encompasses ongoing clinical trials, therapeutic mechanisms of action, routes of administration, and recent developments within the Fibromyalgia treatment landscape.
The Fibromyalgia Pipeline 2025 report provides an exhaustive evaluation of pipeline products, ranging from preclinical stages to marketed therapies. It includes comprehensive details on each drug's mechanism of action, clinical trial…

Chronic Wounds Competitive Landscape 2025: Clinical Trial Analysis, Therapies, F …
As per DelveInsight's assessment, globally, Chronic Wounds pipeline constitutes 7+ key companies continuously working towards developing 8+ Chronic Wounds treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Chronic Wounds Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Wounds Market.
The Chronic Wounds Pipeline report embraces in-depth commercial and clinical assessment…
More Releases for Infliximab
Adalimumab, Infliximab, and Etanercept Biosimilars Market Trends 2024
"The Business Research Company recently released a comprehensive report on the Global Adalimumab, Infliximab and Etanercept Biosimilars Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your…
Infliximab Biosimilar Market Research Report 2024
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Infliximab Biosimilar Market- by Application (Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis and Others), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Direct Distribution Channels), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
Request for Sample Pages: https://www.insightaceanalytic.com/request-sample/1060
According to the latest research by InsightAce Analytic, the global…
Infliximab Biosimilar Insight, 2023 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2023" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning of…
Infliximab Biosimilar Insight, 2023 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2023" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning of…
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning of…
Infliximab and Biosimilar Market 2021 | Detailed Report
Infliximab and Biosimilar Market Forecasts report provided to identify significant trends, drivers, influence factors in global and regions, agreements, new product launches and acquisitions, Analysis, market drivers, opportunities and challenges, risks in the market, cost and forecasts to 2027.
Get Free Sample PDF (including full TOC, Tables and Figures) of Infliximab and Biosimilar Market @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=5048518
The report provides a comprehensive analysis of company profiles listed below:
- Janssen Biotech
- Merck and…